《高盛認股證牛熊證》平醫逆市大升 跑贏同業 留意高槓桿購20469，新上市遠牛53484
正股表現：平醫(1833)昨日升約1.1%，今早繼續上升。早上高開約2.2%後升幅擴大，最高見113.6元。現報112.9元，升約6.8%，跑贏大市及同業。有券商指平醫去年下半年收入升48%，較市場預期高。並料平醫佣金和服務收入可提供額外增長潛力。該行給予「跑贏大市」評級，目標價123元。
此外，昨日升約2.1%及1.7%的藥明生物(2269)及阿里健康(0241)，今早亦見下跌，現報123.1及26.55元，跌約1%及0.9%。
資金流向：觀察個股輪證資金流向，可見近期資金傾向部署平醫認購證，過去4個交易日皆錄得資金流入，合共約820萬元。另一方面，則見藥明牛證於本週二錄得約180萬元資金流入後，昨日獲資金轉向沽出。而阿里健康的牛證則於本週二及本週三共錄得約110萬元資金流入。
產品選擇：投資者如看好平醫，認購證方面可留意屬行使價110至130元間、2個月期以上產品中，槓桿最高之一的平醫購20469。牛證方面可留意屬遠牛的新上市平醫牛53484，與現價有約19元收回距離。
平醫購20469，行使價121.93元，2021年05月05日到期，實際槓桿6.4倍，行使價110至130元間、2個月期以上產品中，槓桿最高之一
平醫牛53484，收回價93.8元，行使價89.8元，換股比率100，槓桿比率4.8倍，新上市遠牛
投資者如看好藥明，可留意新上市的藥明牛52884，與現價有約10%收回距離。投資者如看好阿里健康，可留意新上市的里康牛53480，與現價有約4.6元收回距離。
藥明牛52884，收回價110元，行使價108.5元，換股比率100，槓桿比率7.9倍，新上市、相近收回價牛證中槓桿最高
里康牛53480，收回價22元，行使價21.6元，換股比率50，槓桿比率4.9倍，新上市
註: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/~
重要聲明:
以上資訊由第三方提供，AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告，不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料，本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
